June 12 (Reuters) - The U.S. Food and Drug Administration said on Friday it has approved the expanded use of Sanofi's (SASY.PA), opens new tab type 1 diabetes injection in children aged 8 to ‌17 years ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

Last month many mathematicians were shocked by OpenAI’s announcement that artificial intelligence had solved geometry’s famous “unit distance” problem. For some, the achievement was exciting. But ...

A week after OpenAI made headlines with an A.I.-generated proof, a new “declaration” by 16 experts raises concerns that the technology threatens math as a discipline. By Siobhan Roberts Recently there ...

IPO mania has begun, and nothing kickstarts initial public offerings like spreadsheets flashing green to incite the crowd. SpaceX’s recent S-1 filing promoted an “actionable total addressable market” ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. News about AI math problem raises realization that finding counterexamples can be extremely ...

Lea Uradu, J.D., is a Maryland state registered tax preparer, state-certified notary public, certified VITA tax preparer, IRS annual filing season program participant, and tax writer. Vikki Velasquez ...

Not even a week into the WNBA season, several teams are already shorthanded—and a couple have already secured salary cap hardship exceptions. Both the Liberty and Valkyries received emergency hardship ...

LAS VEGAS — Off-label use of GLP-1 drugs by people with type 1 diabetes (T1D) did not lead to diabetic ketoacidosis (DKA) or pancreatitis in a large 1-year single-center study. Moreover, GLP-1 agonist ...

A surprising new clinical trial has revealed that metformin—a cheap, century-old drug widely used for type 2 diabetes—may help people with type 1 diabetes in an unexpected way. While researchers ...

Not too long ago I would have said I was one of the least likely people to be tempted by GLP-1s like Wegovy or Zepbound. My weight has always been average. I have no medical conditions, and more than ...

For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity and a threat to their businesses. About one in every eight U.S. adults is currently taking a ...